Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00163852 |
Recruitment Status
: Unknown
Verified September 2005 by Bayside Health.
Recruitment status was: Recruiting
First Posted
: September 14, 2005
Last Update Posted
: September 14, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Adult cystic fibrosis (CF) patients admitted with an acute infection complicated by acid-base disturbance and decreased ventilation will be studied.
They will receive salt replacement to correct the acid-base disturbance and possibly their ventilation.
Assessment of symptoms (questionnaire), acid-base and electrolyte status (blood and urine tests) ventilation (overnight oxygen and carbon dioxide monitoring non-invasively) and sleep-wake pattern (actigraphy) will be carried out.
Study hypothesis: Acute volume and electrolyte replacement corrects hypochloremic hypovolemic metabolic alkalosis and compensatory hypoventilation/ hypercapnia in acute exacerbations of cystic fibrosis.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cystic Fibrosis | Drug: Normal saline IV, salt tablets | Phase 2 Phase 3 |
Background: Hypochloremic hypovolemic metabolic alkalosis contributes to hypercapnia in acute exacerbations of cystic fibrosis. Treatment of the metabolic alkalosis with volume and sodium chloride (NaCl) replacement could reduce hypoventilation and hypercapnia, thereby improving symptoms, sleep patterns and daytime activity level. This would avoid unnecessary treatment with non-invasive ventilation.
Hypothesis: Volume and NaCl replacement corrects hypochloremic hypovolemic metabolic alkalosis and compensatory hypoventilation/ hypercapnia in acute exacerbations of cystic fibrosis and results in symptomatic improvement.
Entry criteria:
- Adult cystic fibrosis patient
- Admission with acute exacerbation
- PaCO2 > 45 mmHg
- Primary metabolic alkalosis (acid-base diagram of Stinebaugh and Austin)
- Serum chloride (Cl) ≤ 98 mmol/L
- Serum albumin (alb) > 25 mmol/L
Intervention:
- Normal saline intravenously day(D)1,2,3. (Replace greater of Cl deficiency or acute weight loss, with 2/3 on D1 and remainder D2, D3)
- NaCl tablets 3 tds D4 to 10 (calculated to replace 7 mmol NaCl loss in 60 kg subject)
Random allocation to either:
- Intervention + standard care (including standard dietary advice) D1-10
- Standard care alone (including standard dietary advice) D1-10
Primary outcome measures: (D1, D4, D10)
- PaCO2 (performed at same time of day as admission ABG’s)
- Acid-base status (Stinebaugh and Austin, ABG’s)
- Serum chloride
- Overnight oximetry (% night SpO2<90%) and PtcCO2 (rise in CO2 overnight)
Secondary outcome measures: (D1, D4, D10)
- Serum albumin, sodium
- Body mass index (BMI)
- Spirometry (D1, D10)
- Headache scale
- Epworth sleepiness scale
- Wrist actigraphy (circadian rhythm and daytime activity level)(D1-10)
- Urinary chloride, potassium, sodium, pH, osmolality
- Baseline ABG’s as stable outpatient (within 3 months, pre or post admission)
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Salt Replacement for Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis |
Study Start Date : | February 2004 |
Study Completion Date : | February 2006 |

- Primary outcome measures: (Day1, D4, D10)
- •PaCO2 (performed at same time of day as admission ABG’s)
- •Acid-base status (Stinebaugh and Austin, ABG’s)
- •Serum chloride
- •Overnight oximetry (% night SpO2<90%) and PtcCO2 (rise in CO2 overnight)
- Secondary outcome measures: (Day1, D4, D10)
- •Serum albumin, sodium
- •Body mass index (BMI)
- •Spirometry (D1, D10)
- •Headache scale
- •Epworth sleepiness scale
- •Wrist actigraphy (circadian rhythm and daytime activity level)(D1-10)
- •Urinary chloride, potassium, sodium, pH, osmolality
- •Baseline ABG’s as stable outpatient (within 3 months, pre or post admission)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Adult cystic fibrosis patient
- Admission with acute exacerbation (criteria- fall in FEV1 > 10% from best in last 12/12, change in sputum volume and colour, new pulmonary infiltrate)
- PaCO2 > 45 mmHg on admission
- Primary metabolic alkalosis (acid-base diagram of Stinebaugh and Austin)
- Serum chloride (Cl) ≤ 98 mmol/L
- Serum albumin (alb) ≤ 25 mmol/L
Exclusion Criteria:
Concurrent diuretic therapy Concurrent glucocorticoid therapy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00163852
Contact: Alan C Young, MBBS, FRACP | 613 9276 2000 ext pager 4576 | alan.young@med.monash.edu.au | |
Contact: Matthew T Naughton, MBBS, FRACP | 613 9276 2000 ext 3770 | m.naughton@alfred.org.au |
Australia, Victoria | |
The Alfred | Recruiting |
Melbourne, Victoria, Australia, 3181 | |
Contact: Alan C Young, MBBS 613 9276 2000 ext pager 4576 alan.young@med.monash.edu.au | |
Sub-Investigator: Alan C Young, MBBS |
Principal Investigator: | Matthew T Naughton, MBBS, MD | The Alfred |
ClinicalTrials.gov Identifier: | NCT00163852 History of Changes |
Other Study ID Numbers: |
14/04 |
First Posted: | September 14, 2005 Key Record Dates |
Last Update Posted: | September 14, 2005 |
Last Verified: | September 2005 |
Keywords provided by Bayside Health:
Cystic fibrosis Metabolic alkalosis Hypercapnia Salt replacement |
Additional relevant MeSH terms:
Fibrosis Cystic Fibrosis Alkalosis Pathologic Processes Pancreatic Diseases Digestive System Diseases |
Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Acid-Base Imbalance Metabolic Diseases |